Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE guidance informed by SHTAC report on Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis

Published: 29 June 2021
Oesophagus
Eosinophilic oesophagitis (EoE) is a condition in which the oesophagus (gullet) becomes inflamed

The National Institute for Health and Care Excellence (NICE) has issued guidance to the National Health Service (NHS) on the use of Budesonide orodispersible tablet (ODT) for inducing remission of eosinophilic oesophagitis informed by a report produced by SHTAC.

NICE’s guidance recommends budesonide as an orodispersible tablet (ODT) as an option for inducing remission of eosinophilic oesophagitis in adults.

This recommendation is not intended to affect treatment with budesonide ODT that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

NICE’s guidance is informed by an evidence review group report prepared by SHTAC, which critically appraised the drug company’s submission to NICE’s Single Technology Appraisal process.

For more information about SHTAC’s previous research on gastrointestinal conditions please visit our Research page.

Privacy Settings